Superworth

Kiniksa Pharmaceuticals International EV/EBIT KNSA

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2023.

Today, Oct 23, 2026
54.6×
4-year median
48.1×
Against its 4-year history
58th
percentile: 0 is its lowest day, 100 its highest
4-year range
23.6× to 492×
Peer median
57.7×

Kiniksa Pharmaceuticals International's EV/EBIT is 54.6× as of Oct 23, 2026.

That is above its 4-year median of 48.1×, close to the middle of its last 4 years.

Over that time it ranged from 23.6× in Oct 2023 to 492× in Aug 2025.

The median for 10 large drugmakers of a similar size is 57.7×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far54.6×35.0×85.9×
202574.5×64.5×492×
2024n/m a value too high to mean anything
202323.6×23.6×68.7×

Against its peers

Companies in Drug Manufacturers - General nearest Kiniksa Pharmaceuticals International's size, closest first, today.

CompanyEV/EBIT
KNSAKiniksa Pharmaceuticals International54.6×
LGNDLigand Pharmaceuticals57.7×
AMRXAmneal Pharmaceuticals18.3×
ALKSAlkermes plc.69.6×
TGTXTG Therapeutics62.2×
INDVIndivior Pharmaceuticals7.8×
PTGXProtagonist Therapeutics140×
ARQTArcutis Biotherapeutics111×
CORTCorcept Therapeuticsn/m
LQDALiquidia21.7×
OGNOrganon9.5×
Peer median57.7×

Where Kiniksa Pharmaceuticals International ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Kiniksa Pharmaceuticals International

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.